Signature Wealth Management Group Raises Stock Position in Zoetis Inc. (NYSE:ZTS)

Signature Wealth Management Group boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 9.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,519 shares of the company’s stock after buying an additional 784 shares during the quarter. Signature Wealth Management Group’s holdings in Zoetis were worth $1,551,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. boosted its stake in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in Zoetis in the third quarter valued at approximately $31,000. Dunhill Financial LLC boosted its stake in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Asset Planning Inc acquired a new stake in Zoetis in the fourth quarter valued at approximately $58,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.8 %

ZTS stock opened at $161.33 on Friday. The stock has a market capitalization of $72.24 billion, a P/E ratio of 29.49, a P/E/G ratio of 2.78 and a beta of 0.94. The firm has a 50-day simple moving average of $166.82 and a 200-day simple moving average of $176.15. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.24%. Zoetis’s dividend payout ratio is currently 36.56%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Piper Sandler lifted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Finally, Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average target price of $215.90.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.